Glancy Prongay Wolke & Rotter LLP is continuing its investigation into Alnylam Pharmaceuticals for possible violations of federal securities laws. The investigation follows Alnylam's July 30, 2026 announcement of second quarter results, in which the company lowered its full-year 2026 TTR product sales guidance by approximately $200 million, citing a normalization of growth in second-line volume after initial pent-up demand was satisfied. On that news, Alnylam shares fell as much as $81.25, or 28.35%, in intraday trading, injuring investors. The law firm is urging shareholders who lost money to contact them about potentially pursuing claims to recover their losses.
Alnylam Pharmaceuticals IncLowered full-year 2026 TTR product sales guidance by ~$200M, causing shares to drop 28.35%.